• LAST PRICE
    43.9600
  • TODAY'S CHANGE (%)
    Trending Up0.1100 (0.2509%)
  • Bid / Lots
    35.0000/ 1
  • Ask / Lots
    50.0000/ 1
  • Open / Previous Close
    44.2200 / 43.8500
  • Day Range
    Low 43.4500
    High 44.4400
  • 52 Week Range
    Low 27.9850
    High 50.9900
  • Volume
    275,411
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 43.85
TimeVolumeXENE
09:32 ET252743.565
09:36 ET40043.57
09:38 ET50043.935
09:39 ET761544.26
09:43 ET10044.365
09:45 ET10044.15
09:50 ET10044.345
09:52 ET60044.22
09:54 ET130044.14
09:56 ET110043.7958
09:57 ET804944.025
09:59 ET30043.98
10:01 ET560044.23
10:06 ET62843.9
10:08 ET50043.79
10:12 ET10043.995
10:15 ET70043.82
10:17 ET10043.81
10:21 ET40043.785
10:32 ET20043.5
10:33 ET70043.64
10:35 ET10043.63
10:39 ET10043.62
10:42 ET50043.71
10:46 ET30043.69
10:48 ET40043.59
10:53 ET40043.61
10:57 ET600743.88
11:00 ET81943.875
11:02 ET153343.89
11:04 ET20043.82
11:08 ET70043.86
11:09 ET320143.99
11:11 ET30044
11:18 ET192843.9
11:20 ET200043.89
11:24 ET30043.88
11:26 ET100043.96
11:29 ET25843.97
11:31 ET10043.945
11:33 ET80043.88
11:36 ET10043.76
11:42 ET10043.91
11:44 ET10043.89
11:47 ET20043.83
11:49 ET10043.92
11:51 ET23343.89
11:54 ET20043.92
11:56 ET10044.02
11:58 ET30043.972
12:02 ET20043.95
12:03 ET60043.91
12:05 ET20043.94
12:07 ET93943.985
12:12 ET10044.08
12:14 ET80044.03
12:18 ET286643.92
12:23 ET52543.64
12:25 ET10043.7
12:36 ET40043.7
12:38 ET10043.84
12:39 ET40043.57
12:41 ET11543.7
12:43 ET177343.7
12:54 ET20043.705
12:57 ET10043.82
12:59 ET48243.7
01:01 ET10043.795
01:03 ET10043.81
01:08 ET10043.81
01:10 ET50043.79
01:12 ET10043.7
01:15 ET20043.79
01:17 ET20043.65
01:19 ET22343.8
01:24 ET10043.8
01:28 ET10043.792
01:30 ET10043.8
01:35 ET120643.7
01:37 ET10043.7
01:44 ET10043.79
01:46 ET10043.7
01:48 ET148244.03
01:51 ET10043.99
02:04 ET11144.03
02:06 ET15344.04
02:11 ET10044.042
02:13 ET44843.91
02:15 ET30344.04
02:18 ET13243.95
02:20 ET90043.94
02:22 ET80043.86
02:26 ET20043.93
02:29 ET40043.84
02:33 ET20043.835
02:36 ET70043.88
02:38 ET422043.875
02:40 ET63543.85
02:42 ET10043.865
02:44 ET10043.84
02:45 ET50243.875
02:47 ET40043.865
02:49 ET10043.94
02:51 ET10043.875
02:56 ET20043.875
02:58 ET20043.93
03:00 ET30043.92
03:02 ET20043.85
03:03 ET10043.96
03:05 ET90043.885
03:07 ET20043.885
03:09 ET66843.885
03:12 ET41943.885
03:18 ET10043.885
03:21 ET10043.885
03:23 ET26543.895
03:25 ET30043.94
03:27 ET70043.97
03:30 ET20043.94
03:32 ET30043.945
03:34 ET48343.89
03:36 ET100043.875
03:39 ET105943.85
03:41 ET40043.93
03:43 ET20043.915
03:45 ET101143.87
03:48 ET105643.915
03:50 ET100043.945
03:52 ET456943.965
03:54 ET351743.985
03:56 ET691043.99
03:57 ET411743.985
03:59 ET853543.96
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesXENE
Xenon Pharmaceuticals Inc
3.3B
-16.2x
---
United StatesBHVN
Biohaven Ltd
3.6B
-6.0x
---
United StatesVSBC
Vitaspring Biomedical Co. Ltd
3.1B
3,311.3x
---
United StatesIDYA
IDEAYA Biosciences Inc
3.5B
-21.2x
---
United StatesMLTX
MoonLake Immunotherapeutics
2.9B
-59.7x
---
United StatesAPGE
Apogee Therapeutics Inc
2.8B
-24.4x
---
As of 2024-07-26

Company Information

Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).

Contact Information

Headquarters
3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
Phone
604-484-3300
Fax
604-484-3450

Executives

President, Chief Executive Officer, Director
Ian Mortimer
Chief Financial Officer
Sherry Aulin
Executive Vice President - Drug Discovery
James Empfield
Executive Vice President - Strategy and Innovation
Robin Sherrington
Chief Medical Officer
Christopher Kenney

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$3.3B
Revenue (TTM)
$0.00
Shares Outstanding
75.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.25
EPS
$-2.71
Book Value
$12.31
P/E Ratio
-16.2x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.